Claudio Viscoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11305561/publications.pdf

Version: 2024-02-01

124 15,778 48 115
papers citations h-index g-index

128 128 128 128 13252

times ranked

citing authors

docs citations

all docs

#	ARTICLE	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5.8	4,375
2	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
3	Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy. Clinical Infectious Diseases, 2012, 55, 943-950.	5.8	855
4	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiâ€infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy, 2019, 39, 10-39.	2.6	545
5	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102, 433-444.	3.5	468
6	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	3.0	434
7	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	5.8	368
8	Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy. New England Journal of Medicine, 1999, 341, 312-318.	27.0	360
9	Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial. Clinical Infectious Diseases, 2013, 57, 349-358.	5.8	322
10	Epidemiological trends in nosocomial candidemia in intensive care. BMC Infectious Diseases, 2006, 6, 21.	2.9	266
11	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by∢i>Klebsiella pneumoniae∢/i>Carbapenemase–producing∢i>K. pneumoniae∢/i>. Clinical Infectious Diseases, 2019, 68, 355-364.	5.8	265
12	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Critical Care, 2010, 14, R222.	5.8	250
13	Falseâ€Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillinâ€₹azobactam. Clinical Infectious Diseases, 2004, 38, 913-916.	5.8	240
14	Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. Journal of Infection, 2014, 68, 321-331.	3.3	223
15	A Prospective Study on the Epidemiology of Febrile Episodes during Chemotherapy-Induced Neutropenia in Children with Cancer or after Hemopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2007, 45, 1296-1304.	5.8	221
16	Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Reemergence of Gram-Negative Rods and Increasing Antibiotic Resistance. Biology of Blood and Marrow Transplantation, 2009, 15, 47-53.	2.0	189
17	Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk Stratification. Clinical Infectious Diseases, 2005, 40, S240-S245.	5.8	187
18	Ocular Manifestations of Candidemia. Clinical Infectious Diseases, 2011, 53, 262-268.	5.8	171

#	Article	IF	Citations
19	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine, 2013, 39, 2092-2106.	8.2	169
20	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	8.2	165
21	Epidemiology, Species Distribution, Antifungal Susceptibility and Outcome of Nosocomial Candidemia in a Tertiary Care Hospital in Italy. PLoS ONE, 2011, 6, e24198.	2.5	164
22	Fungal Infections in Children With Cancer. Pediatric Infectious Disease Journal, 2006, 25, 634-639.	2.0	141
23	Aspergillus Galactomannan Antigen in the Cerebrospinal Fluid of Bone Marrow Transplant Recipients with Probable Cerebral Aspergillosis. Journal of Clinical Microbiology, 2002, 40, 1496-1499.	3.9	130
24	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	3.3	125
25	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagnostic Microbiology and Infectious Disease, 2007, 58, 325-331.	1.8	104
26	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	5.8	103
27	Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 307-320.	4.4	100
28	Aspergillus meningitis: A rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. Journal of Infection, 2013, 66, 218-238.	3.3	93
29	Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. Journal of Antimicrobial Chemotherapy, 2009, 64, 625-629.	3.0	83
30	Treatment of febrile neutropenia: what is new?. Current Opinion in Infectious Diseases, 2002, 15, 377-382.	3.1	75
31	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	3.2	75
32	Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy—EORTC Infectious Diseases Group Trial XV. Journal of Clinical Oncology, 2013, 31, 1149-1156.	1.6	72
33	Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses. Clinical Infectious Diseases, 2001, 33, 95-106.	5.8	68
34	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	3.3	67
35	Combined use of serum (1,3)-Î ² -d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Critical Care, 2017, 21, 176.	5.8	65
36	Bloodstream Infections: The peak of the iceberg. Virulence, 2016, 7, 248-251.	4.4	61

#	Article	IF	Citations
37	Infections caused by KPC-producing (i>Klebsiella pneumoniae (i>: differences in therapy and mortality in a multicentre studyâ€"authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2922-2922.	3.0	60
38	Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: A 13-year experience at a single Italian institution. European Journal of Cancer, 2005, 41, 1439-1445.	2.8	57
39	Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. European Journal of Clinical Pharmacology, 2016, 72, 839-848.	1.9	57
40	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of Secondary Infections in Febrile, Neutropenic Patients with Cancer. Clinical Infectious Diseases, 2005, 40, 239-245.	5.8	56
41	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	2.5	55
42	Forum Report: Issues in Clinical Trials of Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Clinical Infectious Diseases, 2003, 36, S117-S122.	5.8	54
43	Current Status of Newer Carbapenems. Current Medicinal Chemistry, 2009, 16, 564-575.	2.4	53
44	Clinical Performance of the $(1,3)$ - \hat{l}^2 - $\langle scp \rangle d \langle scp \rangle$ -Glucan Assay in Early Diagnosis of Nosocomial Candida Bloodstream Infections. Vaccine Journal, 2011, 18, 2113-2117.	3.1	53
45	Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiologica, 2007, 30, 89-99.	0.1	53
46	Prophylaxis and Treatment of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Results of a Consensus Process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clinical Infectious Diseases, 2009, 49, 1226-1236.	5.8	51
47	Occurrence, presentation and treatment of candidemia. Expert Review of Clinical Immunology, 2012, 8, 755-765.	3.0	51
48	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
49	<i>Pneumocystis jirovecii</i> Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, S114-S120.	5.8	50
50	Meropenem for treating KPC-producing <i>Klebsiella pneumoniae</i> bloodstream infections: Should we get to the PK/PD root of the paradox?. Virulence, 2017, 8, 66-73.	4.4	49
51	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infectious Diseases, 2020, 7, ofaa139.	0.9	49
52	High Levels of \hat{l}^2 - <scp>d</scp> -Glucan in Immunocompromised Children with Proven Invasive Fungal Disease. Vaccine Journal, 2010, 17, 882-883.	3.1	48
53	Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum \hat{I}^2 -lactamase-producing organisms in an intensive care unit. Journal of Antimicrobial Chemotherapy, 2007, 60, 433-435.	3.0	47
54	Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. British Journal of Haematology, 2006, 132, 138-154.	2.5	46

#	Article	IF	Citations
55	Changing epidemiology of candidaemia: Increase in fluconazoleâ€resistant <i>Candida parapsilosis</i> Mycoses, 2020, 63, 361-368.	4.0	45
56	Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit. Critical Care, 2010, 14, 244.	5.8	44
57	Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica, 2015, 100, e373-e376.	3.5	44
58	Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Review of Clinical Pharmacology, 2018, 11, 1219-1236.	3.1	44
59	Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. European Journal of Cancer, Supplement, 2007, 5, 5-12.	2.2	43
60	Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infectious Diseases, 2010, 10, 287.	2.9	42
61	Combination Therapy for Invasive Aspergillosis. Clinical Infectious Diseases, 2004, 39, 803-805.	5.8	41
62	Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. Biology of Blood and Marrow Transplantation, 2018, 24, 109-118.	2.0	41
63	Galactomannan testing might be useful for early diagnosis of fusariosis. Diagnostic Microbiology and Infectious Disease, 2012, 72, 367-369.	1.8	40
64	Trends in the annual incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a 8-year retrospective study in a large teaching hospital in northern Italy. BMC Infectious Diseases, 2015, 15, 415.	2.9	40
65	(1-3)-Â-D-Glucan in Cerebrospinal Fluid Is Useful for the Diagnosis of Central Nervous System Fungal Infections. Clinical Infectious Diseases, 2013, 56, 1511-1512.	5.8	38
66	Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection, 2017, 45, 849-856.	4.7	37
67	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 359-365.	2.0	36
68	Invasive aspergillosis: diagnosis, prophylaxis and treatment. Current Opinion in Hematology, 2008, 15, 586-593.	2.5	36
69	De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period. Biology of Blood and Marrow Transplantation, 2018, 24, 1721-1726.	2.0	36
70	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
71	Galactomannan in Piperacillin-Tazobactam: How Much and to What Extent?. Antimicrobial Agents and Chemotherapy, 2005, 49, 3984-3985.	3.2	29
72	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	2.2	29

#	Article	IF	Citations
73	Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. Journal of Infection and Public Health, 2018, 11, 171-177.	4.1	27
74	Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. JAMA Neurology, 2019, 76, 866.	9.0	27
75	Clinical Evaluation of a $(1,3)$ - \hat{l}^2 - $<$ scp>d $<$ /scp> -Glucan Assay for Presumptive Diagnosis of $<$ i>Pneumocystis jiroveci $<$ /i> Pneumonia in Immunocompromised Patients. Vaccine Journal, 2009, 16, 1524-1526.	3.1	25
76	Non-cultural methods for the diagnosis of invasive fungal disease. Expert Review of Anti-Infective Therapy, 2015, 13, 103-117.	4.4	25
77	Current Role of Echinocandins in the Management of Invasive Aspergillosis. Current Infectious Disease Reports, 2011, 13, 517-527.	3.0	23
78	Risk factors for infections due to carbapenem-resistant Klebsiella pneumoniae after open heart surgery. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 762-768.	1.1	23
79	Factors predisposing cancer patients to infection. Cancer Treatment and Research, 1995, 79, 1-30.	0.5	21
80	Clinical and Laboratory Features Predicting a Favorable Outcome and Allowing Early Discharge in Cancer Patients with Low-Risk Febrile Neutropenia: A Literature Review. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 645-649.	1.8	20
81	Use of $1,3-\hat{l}^2$ -D-glucan in invasive fungal diseases in hematology patients. Expert Review of Anti-Infective Therapy, 2017, 15, 1101-1112.	4.4	20
82	Antibacterial prophylaxis in neutropenic patients. International Journal of Antimicrobial Agents, 2007, 30, 60-65.	2.5	19
83	INVASIVE CANDIDIASIS IN NON-HEMATOLOGICAL PATIENTS Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011007.	1.3	19
84	Bacterial infections in hematopoietic stem cell transplantation recipients. Current Opinion in Hematology, 2014, 21, 451-458.	2.5	19
85	Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. Medical Mycology, 2019, 57, 987-996.	0.7	18
86	Latent Tuberculosis Infection among a Large Cohort of Medical Students at a Teaching Hospital in Italy. BioMed Research International, 2015, 2015, 1-6.	1.9	17
87	Antifungal Prophylaxis and Pre-Emptive Therapy. Drugs, 2009, 69, 75-78.	10.9	16
88	Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system?. Journal of Antimicrobial Chemotherapy, 2011, 66, i55-i58.	3.0	15
89	Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infectious Diseases, 2014, 14, 725.	2.9	14
90	Screening With Serum Galactomannan Might Be Associated With Better Outcome Than Symptom-Triggered Galactomannan Testing in Allogeneic HSCT Recipients With Invasive Aspergillosis. Clinical Infectious Diseases, 2013, 57, 1786-1787.	5.8	13

#	Article	IF	Citations
91	Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course. AIDS Research and Human Retroviruses, 2018, 34, 922-928.	1.1	13
92	Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. Infection, 2019, 47, 59-65.	4.7	12
93	Performance of serum (1,3)â€ÃŸâ€xscp>dâ€glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. Mycoses, 2018, 61, 650-655.	4.0	11
94	Evaluation of Mass Spectrometry-Based Detection of Panfungal Serum Disaccharide for Diagnosis of Invasive Fungal Infections: Results from a Collaborative Study Involving Six European Clinical Centers. Journal of Clinical Microbiology, 2019, 57, .	3.9	11
95	Prophylaxis and Empirical Therapy of Infection in Cancer Patients. , 2015, , 3395-3413.e2.		11
96	Forum Report: Issues in the Evaluation of Diagnostic Tests, Use of Historical Controls, and Merits of the Current Multicenter Collaborative Groups. Clinical Infectious Diseases, 2003, 36, S123-S127.	5.8	10
97	Hepatitis E Virus Infection in an Italian Cohort of Hematopoietic Stem Cell Transplantation Recipients: Seroprevalence and Infection. Biology of Blood and Marrow Transplantation, 2020, 26, 1355-1362.	2.0	10
98	First Report of Chronic Pulmonary Infection by KPC-3-Producing and Colistin-Resistant Klebsiella pneumoniae Sequence Type 258 (ST258) in an Adult Patient with Cystic Fibrosis: TABLE 1. Journal of Clinical Microbiology, 2015, 53, 1442-1444.	3.9	9
99	Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. Expert Opinion on Emerging Drugs, 2013, 18, 263-278.	2.4	8
100	Genotypic Determination of HIV Tropism in a Cohort of Patients Perinatally Infected With HIV-1 and Exposed to Antiretroviral Therapy. HIV Clinical Trials, 2014, 15, 45-50.	2.0	8
101	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	2.2	8
102	Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opinion on Pharmacotherapy, 2019, 20, 751-772.	1.8	8
103	Forum Report: Issues in the Design of Trials of Drugs for the Treatment of Invasive Aspergillosis. Clinical Infectious Diseases, 2003, 36, S113-S116.	5.8	7
104	Emergence of a KPC-3-Producing <i>Escherichia coli</i> ST69 as a Cause of Bloodstream Infections in Italy. Microbial Drug Resistance, 2015, 21, 342-344.	2.0	7
105	Prophylaxis and Empirical Therapy of Infection in Cancer Patients. , 2010, , 3793-3807.		7
106	Reduced Incidence of Carbapenem-Resistant Klebsiella pneumoniae Infections in Cardiac Surgery Patients after Implementation of an Antimicrobial Stewardship Project. Antibiotics, 2019, 8, 132.	3.7	6
107	Invasive Aspergillosis in Malignancy and Stem Cell Transplant Recipients. , 0, , 519-530.		6
108	Biomarkers for Diagnosis and Follow-Up of Invasive Candidiasis: A Brief Review of the ECIL Recommendations. Current Fungal Infection Reports, 2012, 6, 192-197.	2.6	4

#	Article	IF	CITATIONS
109	Recent Advances in the Management of Invasive Candidiasis. Drugs, 2009, 69, 1-3.	10.9	3
110	Inflammation Markers Correlate With Common Carotid Intima-Media Thickness in Patients Perinatally Infected With Human Immunodeficiency Virus 1. Journal of Ultrasound in Medicine, 2013, 32, 763-768.	1.7	3
111	Good tolerability of high dose colistin-based therapy in patients with haematological malignancies. Infection, 2017, 45, 505-511.	4.7	3
112	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL. Journal of the International AIDS Society, 2014, 17, 19718.	3.0	2
113	The Beta-d-glucan Test: Time to Re-Visit Its Utility in IFI Diagnosis. Current Fungal Infection Reports, 2015, 9, 292-301.	2.6	2
114	Gram-Positive Bacterial Infections After Haematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 335-355.		2
115	Epidemiology of invasive fungal diseases in children with solid tumours undergoing autologous haematopoietic stem cell transplantation: a 10â€year experience in a tertiary Italian centre. Mycoses, 2017, 60, 517-520.	4.0	2
116	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. Current Hypertension Reviews, 2018, 14, 48-55.	0.9	2
117	Epidemiology and outcome of <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Klebsiella pneumoniae</i> (KPC-KP) infections in cardiac surgery patients: a brief narrative review. Journal of Chemotherapy, 2019, 31, 359-366.	1.5	1
118	Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient. AIDS Research and Human Retroviruses, 2015, 31, 868-869.	1.1	0
119	Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years. AIDS Research and Human Retroviruses, 2017, 33, 19-20.	1.1	0
120	Prevention and treatment of bacterial infections in hematopoietic cell transplants., 0,, 131-139.		0
121	Invasive Candidiasis in Management of Infections in Cancer Patients. , 2011, , 273-281.		0
122	Infectious Complications of Antineoplastic Chemotherapy in Children with Acute Leukemia or Solid Tumors. Pediatric Cancer, 2013, , 121-138.	0.0	0
123	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0
124	The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research. Studies in Health Technology and Informatics, 2019, 264, 1666-1667.	0.3	0